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The PI3K/Akt1 pathway enhances steady-state 
levels of FANCL
Kim-Hien T. Daoa, Michael D. Rotellia, Brieanna R. Browna, Jane E. Yatesa,b, Juha Rantalac, 
Cristina Tognona, Jeffrey W. Tynera,d, Brian J. Drukera,e,*, and Grover C. Bagbya,b,*
aKnight Cancer Institute, cDepartment of Biomedical Engineering, dDepartment of Cell and Developmental Biology, 
and eHoward Hughes Medical Institute, Oregon Health and Science University, Portland, OR 97239; bNorthwest VA 
Cancer Research Center, VA Medical Center Portland, Portland, OR 97239
ABSTRACT Fanconi anemia hematopoietic stem cells display poor self-renewal capacity 
when subjected to a variety of cellular stress. This phenotype raises the question of whether 
the Fanconi anemia proteins are stabilized or recruited as part of a stress response and pro-
tect against stem cell loss. Here we provide evidence that FANCL, the E3 ubiquitin ligase of 
the Fanconi anemia pathway, is constitutively targeted for degradation by the proteasome. 
We confirm biochemically that FANCL is polyubiquitinated with Lys-48–linked chains. Evalua-
tion of a series of N-terminal–deletion mutants showed that FANCL’s E2-like fold may direct 
ubiquitination. In addition, our studies showed that FANCL is stabilized in a complex with 
axin1 when glycogen synthase kinase-3B is overexpressed. This result leads us to investigate 
the potential regulation of FANCL by upstream signaling pathways known to regulate glyco-
gen synthase kinase-3B. We report that constitutively active, myristoylated-Akt increases 
FANCL protein level by reducing polyubiquitination of FANCL. Two-dimensional PAGE analy-
sis shows that acidic forms of FANCL, some of which are phospho-FANCL, are not subject to 
polyubiquitination. These results indicate that a signal transduction pathway involved in self-
renewal and survival of hematopoietic stem cells also functions to stabilize FANCL and sug-
gests that FANCL participates directly in support of stem cell function.
INTRODUCTION
Fanconi anemia (FA) is a hereditary bone marrow failure syndrome 
associated with developmental defects and cancer predisposition. 
Fifteen human genes have been identified by biochemical and/or 
genetic models that demonstrate key cellular defects characteristic 
of FA (Kee and D’Andrea, 2012). These defects include hypersensi-
tivity to DNA cross-linking agents such as mitomycin C in chromo-
some breakage assays and exaggerated arrest of cells in the G2/M 
phase of the cell cycle. The FA nuclear core complex consists of 
FANCA, B, C, E, F, G, L, and M. FANCL is a RING-type E3 ubiquitin 
ligase that monoubiquitinates FANCD2 and FANCI, a key functional 
role facilitated by other members of the nuclear core complex 
(Meetei et al., 2004; Seki et al., 2007; Alpi et al., 2008; Cole et al., 
2010). The monoubiquitinated FANCD2–FANCI heterodimer com-
plex in turn recruits key proteins involved in homologous recombi-
nation and DNA repair, such as FANCD1/BRCA2, FANCJ/BRIP1, 
FANCN/PALB2, and FANCO/RAD51C (Moldovan and D’Andrea, 
2009). Loss of any one of the FA genes causes human disease. These 
findings suggest nonredundant biological and functional roles for 
the FANC genes in DNA damage responses.
The pathogenesis of bone marrow failure in FA is poorly defined. 
Qualitative and quantitative hematopoietic stem cell defects exist 
and occur in the absence of exogenous DNA-damaging agents 
(Gluckman et al., 1989; Auerbach et al., 1990; Haneline et al., 1999; 
Liu et al., 1999; Larghero et al., 2002; Kelly et al., 2007; Zhang et al., 
2008; Jacome et al., 2009; Raya et al., 2010; Tulpule et al., 2010). 
Metabolic byproducts, such as reactive oxygen (Scarpa et al., 1985; 
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stably expressing mCherry fusion proteins of wild-type FANCL or 
C307A-FANCL using automated software analysis (Figure 1C; n  2). 
Wild-type FANCL is more localized to the nucleus (63.4%) than is 
the ligase-inactive C307A mutant (56.6%). Here we show represen-
tative images. In Supplemental Figure S1, we include a compilation 
of z-stack images as videos (Supplemental Movies 1–6). Using cyclo-
heximide to inhibit new protein synthesis, we showed that the 
steady-state, reduced level of wild-type FANCL is due to increased 
protein turnover compared with C307A-FANCL (Figure 1D; n  4). 
The estimated half-life is calculated as 0.8 h for wild-type FANCL 
versus 1.6 h for C307A-FANCL. We performed additional FANCL 
protein-turnover experiments in the nuclear and cytoplasmic frac-
tions and found that the difference between wild-type and C307A-
FANCL protein turnover is primarily in the cytoplasm (Supplemental 
Figure S2). The nuclear fraction of wild-type FANCL may be slightly 
more stable than that of C307A FANCL (p  0.074). These experi-
ments provide evidence that FANCL is regulated at the posttran-
scriptional level and its protein turnover and nuclear localization are 
dependent in part on its own E3 ubiquitin ligase activity.
Constitutive mechanisms target FANCL for ubiquitination 
and degradation by the proteasome
We next tested whether FANCL protein turnover is regulated by the 
proteasome. 293FT cells were treated with or without bortezomib, a 
26S proteasome inhibitor. The effects on overexpressed FANCL 
were quantified by immunoblot analysis as shown in Figure 2A (n  
3 for mutants; n  4 for wild type). Wild-type FANCL displays the 
greatest relative stabilization with proteasome inhibition compared 
with the ligase-inactive FANCL mutants, suggesting that mecha-
nisms involving autoubiquitination of FANCL may be more respon-
sive to proteasome inhibition. Similar findings were observed when 
we expressed FANCL–enhanced green fluorescent protein (eGFP) 
fusion proteins in HeLa cells and quantified protein levels by flow 
cytometry (Figure 2B; n  4). We then performed ubiquitination as-
says to confirm that FANCL is marked for proteasome degradation 
by polyubiquitination. Here we expressed FANCL (wild type or 
C307A mutant) and hemagglutinin-tagged ubiquitin (HA-Ub). Wild-
type HA-Ub has all seven lysines intact, whereas the Lys-48 HA-Ub 
mutant only has Lys-48 intact for ubiquitin chain extension. These 
studies revealed that FANCL is polyubiquitinated (Figure 2C; n  2). 
As expected, proteasome inhibition greatly stabilized the polyubiq-
uitinated forms of FANCL. Non–FANCL-expressing control cells 
provided confidence that the immunoprecipitated protein being 
evaluated was FANCL and not a nonspecific protein. The facts that 
the Lys-48 HA-Ub mutant can be used for ubiquitin chain extension 
and that these FANCL ubiquitinated species are highly responsive 
to proteasome inhibition provide evidence that FANCL is marked 
for degradation by Lys-48 polyubiquitination. These results are qual-
itative because the C307A mutation may affect FANCL’s binding to 
the antibody in immunoprecipitation/nondenaturing conditions, 
and FANCL is immunoprecipitated from lysates with significantly dif-
ferent steady-state levels (e.g., Figure 1A). Furthermore, these re-
sults cannot be normalized with a high degree of confidence be-
cause polyubiquitinated FANCL presents as a smear on immunoblots, 
and some of the total FANCL may be much higher in molecular 
weight and are not evaluated. Compared to eGFP expression alone, 
there is rapid turnover of FANCL-eGFP expression, and the overall 
level is maintained at a very low level in real-time imaging experi-
ments quantifying mean fluorescence in live cells over time (Supple-
mental Figure S3). Videos are provided as part of Supplemental 
Figure S3 (Movies 7 and 8). Evaluation of N-terminal–deletion FANCL 
mutants in similar ubiquitination assays revealed that the E2-like fold 
Korkina et al., 1992; Zhang et al., 2007) and aldehyde species 
(Langevin et al., 2011; Rosado et al., 2011; Garaycoechea et al., 
2012), are believed to contribute to hematopoietic stem cell loss. In 
addition, Fanconi anemia hematopoietic stem cells are hypersensi-
tive to tumor necrosis factor-A (TNF-A), mip1-A, and interferon-G 
(Broxmeyer et al., 1991; Dufour et al., 2003; Li et al., 2004, 2005, 
2007; Si et al., 2006). Ex vivo exposure of murine Fancc-deficient 
hematopoietic stem cells to TNF-A increases stem cell loss and se-
lects for TNF-A–resistant clonal variants (Li et al., 2005, 2007). These 
findings are particularly relevant to understanding the pathogenesis 
of marrow failure because cytokine levels in sera from FA patients’ 
blood and marrow are much higher than with normal controls 
(Schultz and Shahidi, 1993; Rosselli et al., 1994; Dufour et al., 2003). 
A key recurring defect described in FA hematopoietic stem cells is 
their poor self-renewal capacity when subjected to cellular stresses. 
Until recently, however, there has been little mechanistic and bio-
chemical evidence that FA proteins directly regulate this function in 
hematopoietic stem cells.
We recently reported a biochemical and functional link between 
FANCL and B-catenin, a downstream effector of the Wnt pathway 
(Dao et al., 2012). FANCL ubiquitinates B-catenin with atypical ubiq-
uitin chains (K11 linked), a modification that functionally enhances 
B-catenin activity. Suppression of FANCL significantly disrupted 
Wnt/B-catenin signaling and reduced transcription of downstream 
targets cyclinD1 and c-myc (Dao et al., 2012). These findings sug-
gest that FANCL has a noncanonical function to regulate the Wnt/B-
catenin signaling, a pathway with known functions in hematopoietic 
stem cell self-renewal. During the course of these studies, we sought 
to define how FANCL is itself posttranscriptionally regulated. Here 
we show that FANCL stability is regulated by the ubiquitin-protea-
some pathway in a manner influenced directly by Akt1, suggesting 
that FANCL regulates stem cell function in part through its role as 
a downstream effector of phosphoinositide 3-kinase (PI3K)/Akt1 
signaling.
RESULTS
FANCL expression is regulated in part by its own E3 
ubiquitin ligase activity
Many E3 ubiquitin ligases are known to autoubiquitinate and regu-
late their own protein levels (de Bie and Ciechanover, 2011). We 
examined the posttranscriptional regulation of FANCL in 293FT 
cells by quantifying human wild-type FANCL expression versus the 
ligase-inactive mutant forms, C307A- and W341G-FANCL. The mis-
sense mutations occur in the RING domain and abrogate key amino 
acids involved in the coordination of zinc (Figure 1A). The W341G-
FANCL mutant retains some ability to assemble the nuclear core 
complex and partial E3 ubiquitin ligase activity, whereas the C307A-
FANCL mutation is biochemically inactive (Meetei et al., 2003; Gur-
tan et al., 2006; Hodson et al., 2011). As shown, wild-type FANCL 
expression is lowest compared with the ligase-inactive mutants, 
suggesting that autoubiquitination may play a role in regulating 
FANCL if we assume that the activity of endogenous E3 ligases is 
not affected by wild-type or mutant FANCL overexpression. We 
quantified the relative cytoplasmic and nuclear expression of FANCL 
by immunoblot analysis. Data were normalized to tubulin and SP1 
loading controls. Wild-type FANCL protein was proportionally more 
prominent in the nucleus than in the cytoplasm when compared 
with the ligase-inactive mutants (Figure 1B). These results were 
quantified from seven independent experiments and suggest that 
autoubiquitination may play an important role in the steady-state 
levels of FANCL, as well as in its relative subcellular localization. 
Similar findings were observed by microscopy analysis of HeLa cells 
2584 | K.-H.T. Dao et al. Molecular Biology of the Cell
FANCL ubiquitination, suggesting that the region between amino 
acids 114 and 156 may play a role in inhibiting FANCL ubiquitina-
tion. Two-dimensional (2D) PAGE analysis of whole-cell extracts 
(Figure 2E; n  2) demonstrated that treatment of cells with borte-
zomib stabilized total FANCL and ubiquitinated forms of FANCL 
(ELF) domain may play a role in directing ubiquitination (Figure 1A, 
schematic, and Figure 2D; n  4). Deletion of amino acids 78–114 
resulted in a substantial loss of ubiquitinated FANCL species, 
whereas total del-114-FANCL-eGFP protein levels remained rela-
tively stable. Further deletion of FANCL resulted in partial rescue of 
FIGURE 1: FANCL expression is regulated in part by its own E3 ubiquitin ligase activity. (A) Left, schematic of human 
FANCL protein and its domains. Highlighted by red arrowheads are the ligase-inactive FANCL mutants C307A and 
W341G. Right, steady-state expression of wild-type and ligase-inactive FANCL mutants as determined by immunoblot 
analysis. Relative expression (numbers below FANCL blot) was normalized to C307A and to tubulin loading controls 
from four experiments. These results were similarly observed in the untreated controls in the experiments shown in 
Figure 2A. (B) Nuclear and cytoplasmic expression of wild-type and ligase-inactive mutants in 293FT cells. A 
representative blot. Comparable purity of fractions was demonstrated by tubulin expression in the cytoplasmic fractions 
and SP1 in the nuclear fractions. The graph displays the quantitation of relative protein expression to C307A-FANCL for 
each of the nuclear and cytoplasmic fractions, relative to the respective loading control for each lane, from seven 
independent experiments (mean o SD; *p  0.033 and **p  0.030 when we compared cytoplasmic wild type vs. C307A 
and vs. W341G mutants, respectively). Nuclear expression of wild type vs. mutants was not significantly different. 
(C) HeLa cells expressing mCherry-fusion proteins of FANCL were evaluated by microscopy. DAPI was used to stain 
nuclei. Scale bar, 50 µm. Nuclear and cytoplasmic mean fluorescence were quantified by software as detailed in 
Materials and Methods (average of n  2). (D) Protein turnover experiments were performed in 293FT cells using 
cycloheximide. Cell lysates were harvested at the indicated time after the addition of cycloheximide. Right, graphical 
summary of four independent experiments and the calculated half-life (mean o SEM). Densitometry of bands were 
normalized to time 0. Left, representative blot from one such experiment.
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GSK3B stabilizes FANCL protein
We then performed experiments to test the observation that FANCL 
is stabilized by GSK3B. When we overexpressed GSK3B compared 
with a vector-control or a kinase-dead version of GSK3B (exon 
8/9-deleted GSK3B; Abrahamsson et al., 2009), we observed an in-
crease in total FANCL levels (Figure 4A; n  3). These results suggest 
that the stabilization of FANCL is dependent in part on the kinase 
activity of GSK3B. In cycloheximide experiments, we observed 
stabilization of both wild-type FANCL and ligase-inactive C307A-
FANCL with GSK3B overexpression. A stable pool of FANCL re-
mained at the 6-h time point with GSK3B overexpression compared 
with vector-control–transfected cells (Figure 4B; n  4). The ligase-
inactive C307A-FANCL mutant was stabilized to a higher degree 
than wild-type FANCL. These results suggest that GSK3B stabilizes 
FANCL in part by an E3-ligase–independent mechanism but that 
having intact ligase activity also plays a role in stabilizing FANCL 
(Figure 4B). Suppression of endogenous GSK3B by short hairpin 
RNA (shRNA) expression reduced the steady-state level of FANCL 
compared with control shRNA expression (Figure 4C; n  3). We 
generated a T178A point mutation at a putative GSK3B phosphory-
lation site in FANCL identified by the NetPhosK1.0 and KinasePhos 
programs (Figure 4D, top, left). This site shares the S/T-X-X-X-pS/pT 
motif found in other known GSK3B substrates (Dajani et al., 2001). 
Our studies with the T178A mutant showed that this motif is impor-
tant for the stabilization of FANCL. Steady-state expression of 
T178A-FANCL is consistently lower than that of the wild-type FANCL 
(Figure 4D, top, right). With complete knockdown of GSK3B by 
shRNA expression, however, which would inhibit the kinase activity 
and the scaffolding function of GSK3B, the T178A-FANCL mutant 
demonstrated similar protein turnover to wild-type FANCL (Figure 
4D, bottom; n  3). Together these results suggest that GSK3B sta-
bilizes FANCL protein, potentially through a complex involving axin1 
(Figure 3C), by phosphorylation. This is further supported by the 2D 
PAGE analysis of FANCL, which showed that acidic or phospho 
forms of FANCL are not subject to polyubiquitination (Figure 2E).
PI3K/Akt activation inhibits GSK3B by Ser-9 
phosphorylation and increases FANCL expression
To explore the biological significance of our novel findings show-
ing that GSK3B stabilizes FANCL via a scaffold that may facilitate 
its phosphorylation, we tested whether the PI3K/Akt pathway 
regulates this interaction. PI3K/Akt is a survival pathway that sig-
nals in part through GSK3B (Chappell et al., 2011). Activation of 
the PI3K/Akt pathway leads to phosphorylation of GSK3B at ser-
ine 9, resulting in a kinase-inactive form through a pseudosub-
strate mechanism (Kockeritz et al., 2006). Our studies here reveal 
a more complex interaction between GSK3B and FANCL. Using 
flow cytometry, we observed that overexpression of a constitu-
tively active Akt1 (myristoylated Akt1) stabilized FANCL-eGFP 
compared with vector-control conditions (Figure 5A; n  4). We 
confirmed this regulation by conventional immunoblot analysis 
and quantified the average fold stabilization in three independent 
experiments (Figure 5B). There was ^2.5-fold increase in total 
FANCL expression with activated Akt1 expression compared with 
control. As expected, overexpression of myristoylated Akt1 in-
creased phosphoserine-9–GSK3B compared with vector-control 
conditions, whereas total GSK3B levels remained unaffected. The 
use of 2D PAGE showed that myr-Akt1 expression was associated 
with markedly reduced ubiquitinated FANCL forms compared 
with control-transfected cells (Figure 5C; n  2). Therefore Akt1 
stabilizes FANCL in part by directly or indirectly reducing FANCL 
ubiquitination. Using another approach to verify that Akt1 
(Figure 2E, blue bracket). We performed similar analyses of the 
ligase-inactive mutants, C307A and W341G, and detected that the 
mutants are also polyubiquitinated (Supplemental Figure S4). Acidic 
forms of FANCL (those species with a lower pI; red asterisks) were 
not subjected to ubiquitination, suggesting that phosphorylation 
protects FANCL from polyubiquitination. We confirmed that some 
of these acidic forms of FANCL are phosphorylated in experiments 
in which lysates were desalted and treated with calf intestinal alka-
line phosphatase (Figure 2F; n  2). Compared to control conditions 
(lysates spiked with alkaline phosphatase inhibitors EDTA and ortho-
vanadate), the abundance of the acidic forms of FANCL was re-
duced with alkaline phosphatase treatment. In Figure 2G, we ana-
lyze FANCL abundance in whole-cell lysate, flowthrough, and 
phospho-enriched fractions (n  2) and determine that FANCL is 
more abundant in the phospho-enriched fractions than in the 
flowthrough fractions (Figure 2G, top, right). We confirmed that the 
approach was efficient in enriching for phosphorylated proteins 
(Figure 2G, left). We demonstrate that FANCL is phosphorylated at 
serine and threonine residues by immunoprecipitation studies 
(Figure 2G, bottom, right). Together these results provide evidence 
that FANCL is regulated by phosphorylation and ubiquitin-mediated 
proteasome degradation.
FANCL and GSK3B directly interact in a complex involving 
axin1
Because we previously observed a protein–protein interaction be-
tween FANCA, C, and G with B-catenin (Dao et al., 2012), we hy-
pothesized that GSK3B, a serine-threonine kinase known to regulate 
a number of proteins by phosphorylation, might have a role in regu-
lating FANCL ubiquitination by phosphorylation. We first tested 
whether FANCL binds to GSK3B in coimmunoprecipitation experi-
ments. In cell extracts, we observed coimmunoprecipitation of 
FANCL and GSK3B when using a V5 or a GSK3B antibody but not 
with a FANCL antibody. We believe that this is due to the fact that 
the entire protein–protein binding domain was used to generate the 
mouse antibody. Therefore we believe the FANCL antibody cannot 
pull down GSK3B in the reverse immunoprecipitation because of 
epitope masking. The specificity of the immunoprecipitations was 
determined by carrying out parallel immunoprecipitations with V5-
tagged LacZ control and isotype control antibodies as shown 
(Figure 3A, left; n  4). We also demonstrated that the interaction is 
direct by performing coimmunoprecipitation studies with purified 
glutathione S-transferase (GST)–fusion proteins (Figure 3A, right). 
Coimmunoprecipitation of endogenous FANCL with GSK3B was 
also demonstrated (Figure 3A, middle; n  3). Using microscopy, we 
observed colocalization of GSK3B-eGFP and FANCL-mCherry fu-
sion proteins primarily in the cytoplasm (Figure 3B; n  2). Pearson’s 
coefficient approached 1.0 for select random cells evaluated. Their 
colocalization appeared in aggresome-like structures and disrupted 
FANCL’s nuclear localization. We also tested whether the interaction 
between FANCL and GSK3B is facilitated by axin1, a scaffolding 
protein in the well-described destruction complex that regulates B-
catenin phosphorylation and its subsequent polyubiquitination. Of 
interest, overexpression of axin1 stabilizes FANCL expression 
(Figure 3C, input lanes). We observed that axin1 coimmunoprecipi-
tates with FANCL and GSK3B to a greater degree than isotype con-
trol antibody, which nonspecifically pulled down some axin1 
(Figure 3C; n  3). These results contrast with the roles of GSK3B and 
axin1 in regulating B-catenin and is opposite of what we had origi-
nally hypothesized. Instead of targeting FANCL for degradation, the 
FANCL-GSK3B-axin1 complex may stabilize FANCL at the posttran-
scriptional level.
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FIGURE 2: Constitutive mechanisms target FANCL for ubiquitination and proteasome degradation. (A) Cells expressing 
the wild-type or ligase-inactive FANCL mutant were treated with or without bortezomib, a 26S proteasome inhibitor. 
Numbers below the blots show the average change in expression relative to no-bortezomib lanes from independent 
experiments (n  3 for mutants; n  4 for wild type; p values displayed beneath blot). (B) Expression of eGFP-fusion 
proteins of wild-type and ligase-inactive FANCL mutants in HeLa cells was quantified by flow cytometry with or without 
bortezomib. Fold change was calculated relative to the untreated condition for each FANCL type, and the average was 
taken from four independent experiments and graphed as mean o SD. (C) Ubiquitination assays were performed in 
293FT cells with or without bortezomib and carried out with wild-type FANCL (wt) or C307A-FANCL (mu). The no-
FANCL condition (0) demonstrates specificity of immunoprecipitation (IP) with FANCL antibody and ubiquitinated 
products as detected by HA antibody detecting HA-tagged wild-type or Lys-48 ubiquitin. Bracket denotes the 
polyubiquitinated FANCL species. This is a representative blot of two experiments. (D) The N-terminal truncation 
mutants of human FANCL were subjected to ubiquitination assays in 293FT cells as described. Deletion mutants 1–7 as 
follows: 1 (deleted amino acids 1–56), 2 (deleted amino acids 1–77), 3 (deleted amino acids 1–113), 4 (deleted amino 
acids 1–155), 5 (deleted amino acids 1–178), 6 (deleted amino acids 1–212), 7 (deleted amino acids 1–306). Top, IP with 
FANCL and probed for HA-tagged ubiquitinated products. Bottom, same blot probed for total FANCL. This is a 
representative blot of four experiments. (E) The 2D PAGE analysis of 293FT cell extracts under conditions of FANCL 
overexpression with or without bortezomib treatment. First dimension was separated by pI using the ZOOM strip with 
pH range of 4–7. The predicted pI of FANCL is 6.02 (ExPASy Compute pI/Mw tool). Ubiquitin molecules conjugated to 
FANCL are not predicted to shift its pI substantially. A ubiquitin molecule has a predicted theoretical pI/MW of 
6.56/8564.84 using a similar ExPASy analysis. Second dimension was separated by SDS–PAGE and resolved by 
molecular weight. Blot was probed for FANCL. This blot is representative of two experiments. Ubiquitinated FANCL 
species marked by a blue bracket; acidic forms of FANCL marked by red asterisks. (F) Lysates were desalted and 
treated with calf intestinal alkaline phosphatase in the presence or absence of orthovanadate and EDTA, which 
completely inactivates alkaline phosphatase. Blots were probed for FANCL and tubulin. The overall abundance of acidic 
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forms of FANCL was reduced in two independent experiments with alkaline phosphatase treatment. (G) Whole-cell 
lysate (WCL), flowthrough (FT, phospho-poor fraction), and phospho-enriched (P) fractions were probed for 
phosphoserine and phosphothreonine proteins (left). Red arrowhead denotes where FANCL is expected. There was a 
significant enrichment of phosphoproteins in the eluted fractions. The same cell lysates were evaluated for total FANCL 
(top, right; n  2). FANCL was immunoprecipitated from 293FT cells overexpressing FANCL or not overexpressing 
FANCL (–) and probed with a phosphoserine or phosphothreonine antibody separately (n  3).
DISCUSSION
Our group is interested in investigating the alternative functions of 
the FA pathway and their potential interaction with other signaling 
pathways with known critical roles in maintaining hematopoietic 
stem cell function. FA hematopoietic stem cells display poor self-
renewal capacity when subjected to a variety of cellular stresses 
(Scarpa et al., 1985; Korkina et al., 1992; Dufour et al., 2003; Li et al., 
2004, 2005, 2007; Si et al., 2006; Zhang et al., 2007; Langevin et al., 
2011; Rosado et al., 2011; Garaycoechea et al., 2012). Here we fo-
cused on dissecting the posttranscriptional regulation of FANCL, 
the E3 ubiquitin ligase of the FA pathway. Among the FA core com-
plex members, we view FANCL as a key point of functional and 
regulates FANCL posttranscriptionally, we suppressed Akt1 by 
shRNA expression and observed reduced steady-state levels of 
wild-type FANCL-eGFP and C307A-FANCL-eGFP (Figure 5D; at 
least three experiments for each shRNA). We noted, however, 
that eGFP control expression was also reduced but to an overall 
lesser degree than FANCL (p values are indicated in the figure 
legend for all comparisons). Interpretation of these results is lim-
ited by the fact that general suppression of Akt1 may cause these 
effects indirectly. Despite this limitation, the studies we describe 
here support the notion that Akt1 stabilizes FANCL at the post-
transcriptional level and this is partly due to reduced ubiquitina-
tion of FANCL.
FIGURE 3: FANCL and GSK3B directly interact in a complex involving axin1. (A) 293FT cells overexpressing LacZ-V5 or 
GSK3B-V5 and FANCL were immunoprecipitated with anti-V5 and probed for FANCL (left; n  4). We confirmed 
successful immunoprecipitation of V5-tagged proteins as shown in the blot. We did not observe coimmunoprecipitation 
when a FANCL antibody was used, possibly due to epitope masking (data not shown). Right, GST-fusion proteins were 
purified from Escherichia coli and subjected to immunoprecipitation studies. Isotype antibody control, mouse (M), and 
rabbit (R) were included as shown. Blot was probed for FANCL and for GSK3B. Middle, coimmunoprecipitation of 
endogenous FANCL and GSK3B was also demonstrated in HeLa cells (n  3). (B) Microscopy analysis of HeLa cells 
expressing FANCL-mCherry and GSK3B-eGFP reveal colocalization primarily in the cytoplasm. Pearson’s coefficient 
approached 1 when random cells were analyzed, indicating colocalization. Scale bar, 20 µm. (C) Immunoprecipitation 
was performed in cells expressing axin1, FANCL, and GSK3B with either isotype control antibody (IgG) or an axin (Ax) 
or GSK3B (Gsk) antibody and probed for axin and FANCL as shown (n  3). The enhanced expression of FANCL by axin1 
overexpression is quantified as shown, and the corresponding actin loading controls are included.
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FIGURE 4: GSK3B stabilizes FANCL expression. (A) FANCL was overexpressed with vector-control (VC), wild-type 
GSK3B, or a kinase-inactive, exon 8/9–deletion GSK3B version ($8,9) in 293FT cells, and steady-state levels of FANCL 
were analyzed by immunoblot analysis. Tubulin was used as a loading control. Numbers represent densitometric average 
of relative FANCL expression to VC in three experiments. (B) Protein turnover experiments using cycloheximide (CHX) to 
block new protein synthesis were performed in 293FT cells. Cells expressed wild-type or C307A-FANCL with GFP or 
GSK3B overexpression. A representative blot probing for FANCL and tubulin is shown for cells coexpressing GSK3B, and 
the quantification from four independent experiments is graphed (mean o SD). Densitometries of bands were normalized 
to time 0. The half-life was not calculated, as the protein turnover did not meet first-order decay kinetics. Note that this 
experiment evaluates turnover of overexpressed FANCL, as endogenous FANCL is not detectable in these experiments. 
(C) FANCL protein levels were evaluated by immunoblot analysis of 293FT cell extracts with increasing concentrations of 
GSK3B shRNA (0–1 µg of DNA for a dish of 4-cm2 surface area). Scrambled shRNA was also added to maintain a similar 
amount of total DNA transfected in all conditions. A representative blot from three independent experiments. (D) A 
schematic of the putative S/T-X-X-X-pS/pT GSK3B phosphorylation motif in human FANCL. The T178A mutant was 
generated to test the role of the Thr-178 in FANCL protein stability. A representative blot is shown for protein turnover 
studies performed with GSK3B suppression (GSK3B-shRNA) or without (Scr-shRNA) in 293FT cells. Densitometries of 
bands from three independent experiments were normalized to time 0 and graphed (mean o SD).
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serves as a priming step to recruit other 
ubiquitin-binding protein/E3 ligase com-
plexes. We also observed that autoubiquit-
ination might have an additional role in 
promoting nuclear localization of FANCL 
(Figure 1B). Our results could also be ex-
plained by other mechanisms. For example, 
the C307A mutation might affect its nuclear 
transport or its ability to bind to chromatin 
or other E3 ligases, which might contribute 
to its more diffuse expression in the nucleus 
and cytoplasm compared with wild-type 
FANCL.
The recently solved crystal structure of 
FANCL has uncovered some unique fea-
tures. FANCL possesses three domains, the 
N-terminal ELF, the tandem or double RWD 
domain involved in substrate binding 
(DRWD), and the C-terminal really interest-
ing new gene (RING) involved in E2 binding 
(Cole et al., 2010). The ELF and the double 
RWD domains together form three folds; 
each fold is similar to the ubiquitin-conju-
gating (E2) superfamily. This is a novel struc-
tural arrangement not seen in other E3 
ligases (Cole et al., 2010). We generated a 
series of N-terminal mutations of FANCL 
with the goal of understanding the role of 
the ubiquitin-conjugating folds in facilitat-
ing FANCL ubiquitination. Deletion of the 
N-terminus up to amino acids (aa) 114 in 
FANCL leads to an abrupt loss of ubiquitina-
tion (Figure 2D), suggesting that the region 
between aa 78 and 114 might direct ubiq-
uitination or recruit proteins that enhance 
the efficiency of ubiquitination. Of interest, 
we found that additional truncation up to aa 
179 resulted in partial recovery of ubiquit-
ination, suggesting that this region might 
structurally inhibit ubiquitination. Crystal 
structural analyses of this mutant might 
reveal the basis for these observations.
There are many examples of proteins targeted for polyubiquit-
ination and degradation by an initial phosphorylation signal. B-
Catenin is one such example in which multiple phosphorylations at 
the N-terminal region leads to recruitment of a multiprotein E3 li-
gase complex SCF-B-TrCP (Aberle et al., 1997). We examined 
whether a similar mechanism could regulate FANCL, by performing 
2D PAGE analysis. In contrast to what we expected, we observed 
that acidic forms of FANCL are not ubiquitinated, as shown in Figure 
2E. These results raise the possibility that posttranscriptional regula-
tion of FANCL is tightly regulated by kinases and that phosphoryla-
tion is protective against Lys-48–linked polyubiquitination. We 
confirmed that FANCL is indeed phosphorylated at serine and 
threonine residues (Figure 2G). Based on our previous publication 
(Dao et al., 2012), we tested the role of GSK3B, since we had 
observed that GSK3B modulates the protein level of FANCL.
We observed a direct interaction between FANCL and GSK3B by 
coimmunoprecipitation and by microscopy studies (Figure 3, A and 
B). Our studies also suggest a role for axin1 in this complex, as we 
coimmunoprecipitated FANCL and GSK3B using an axin antibody 
(Figure 3D). GSK3B expression stabilized FANCL, whether we 
signaling divergence, as most E3 ubiquitin ligases are known to 
have multiple protein targets.
Here we provide evidence that FANCL is constitutively targeted 
for degradation by the proteasome. FANCL, like other E3 ligases 
(de Bie and Ciechanover, 2011), likely regulates its own protein lev-
els through autoubiquitination. We compared wild-type versus li-
gase-inactive FANCL protein turnover and showed that autoubiquit-
ination may play a significant role in FANCL degradation (Figure 1D). 
This interpretation is based on the assumption that activity of 
endogenous E3 ligases is not different when wild-type versus ligase-
inactive FANCL mutants are overexpressed in cells. In addition, our 
studies reveal that ubiquitination by another E3 ligase is mechanisti-
cally involved in marking FANCL for degradation by ubiquitination. 
We arrived at this conclusion based on the finding that ligase-inac-
tive mutants also show some degree of protein stabilization with 
proteasome inhibition (Figure 2A). We have not identified the E3 
ligase that might have this role. We confirm that polyubiquitination 
of FANCL occurs with Lys-48 ubiquitin chain extensions (Figure 2C), 
which typically mark proteins for proteasome degradation. It re-
mains to be determined whether autoubiquitination by FANCL 
FIGURE 5: PI3K/Akt activation inhibits GSK3B by Ser-9 phosphorylation and increases 
FANCL expression. (A) GFP was quantified by flow cytometry to reflect steady-state levels of 
FANCL-eGFP with coexpression of vector-control (VC) vs. myristoylated Akt1 (myr-Akt1) in HeLa 
cells. The graph is a summary of four independent experiments (mean o SD; p < 0.003 for all 
three comparisons of VC vs. myr-Akt1 effects). (B) Cells expressing FANCL with GFP vs. 
myristoylated Akt1 were evaluated by immunoblot analysis. HeLa cell extracts were evaluated 
for FANCL, phosphoserine-9–GSK3B, total GSK3B, and tubulin. A representative blot. The graph 
depicts the quantification of relative FANCL expression from three independent experiments 
(mean o SD; p value displayed). (C) Extracts from 293FT cells expressing FANCL with vector 
control or myr-Akt1 were analyzed by 2D PAGE and probed with a FANCL antibody (n  2). 
Green arrow denotes lysates separated by PAGE (separation by size only). Blue brackets denote 
ubiquitinated FANCL forms. (D) Expression of eGFP (control), FANCL-eGFP, or C307A-FANCL-
eGFP in 293FT was evaluated under conditions of scrambled-shRNA expression (Scr) vs. 
Akt1-shRNA expression (two different shRNAs, Akt1shRNA a and Akt1shRNA b). Mean 
fluorescence intensity was quantified by flow cytometry and normalized relative to control cells 
(Scr shRNA control for each eGFP construct). This experiment was performed three 
independent times, and the graph shows the mean o SD. Compared to each individual Scr 
shRNA control, p values are *0.024, **0.0002, ***0.0004. Compared to eGFP control for each 
type of shRNA, p values are †<0.039 for Akt1shRNAa and ‡<0.023 for Akt1shRNAb for the 
FANCL-eGFP and C307A-FANCL-eGFP–expressing cells.
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mediated degradation. These results sug-
gest a role for FANCL as a downstream ef-
fector of PI3K/Akt. However, because these 
pathways inhibit GSK3B by Ser-9 phospho-
rylation, we believe that there are addi-
tional, GSK3B-independent mechanisms 
(e.g., other kinases) involved in regulating 
FANCL and its stabilization. Of importance, 
loss of Akt1 destabilizes FANCL (Figure 5D). 
Additional studies would be necessary to 
prove whether Akt1 has a role in directly 
phosphorylating FANCL. These studies are 
beyond the scope of this work.
We characterized mechanisms of FANCL 
regulation and identified phosphorylation 
as one mechanism regulating ubiquitination 
of FANCL (Figure 6). Our finding that PI3K/
Akt stabilizes FANCL protein level has sev-
eral biological implications. PI3K/Akt has a 
role in cell cycle progression, survival, DNA-
damage response, RNA export via REF/Aly, 
and tumorigenesis (Martelli et al., 2012). 
Phenotypic and functional similarities exist 
between normal stem cells and cancer stem 
cells (Yilmaz and Morrison, 2008). These 
findings suggest that in the context of path-
ological up-regulation of PI3K/Akt, FANCL 
may have an effect on tumor cell survival 
and chemotherapy resistance. Tumor cells 
displaying upregulated FANCL may correct 
DNA lesions more efficiently (Figure 6). In normal tissues and in tis-
sue injury, the functions of FANCL may be protective against exces-
sive cell death and genomic instability. This is apparent in FA pa-
tients, in whom loss of the FA pathway leads to progressive 
hematopoietic stem cell loss and a very high propensity for neoplas-
tic transformation. The fact that PI3K/Akt has emerged as a 
key pathway regulating hematopoietic stem cell function further 
highlights the potential relevance of our finding that FANCL is a 
downstream effector of PI3K/Akt (Figure 6; Polak and Buitenhuis, 
2012). Our studies are the first to characterize posttranslational 
modification of FANCL and to provide mechanistic insights into 
how they could regulate FANCL activity. In addition, we show 
that FANCL protein stabilization is responsive to upstream signaling 
pathways that regulate self-renewal and survival of hematopoietic 
stem cells.
MATERIALS AND METHODS
Cells and culture conditions
293FT and HeLa cells were maintained in 10% fetal bovine serum 
DMEM medium supplemented with nonessential amino acids and 
glutamine. All cells were grown in 5% CO2 humidified incubator at 
37°C. Bortezomib was tested at a concentration ranging from 25 to 
500 nM, depending on the cell type, for 16–24 h.
Constructs
Human cDNAs for FANCL, GSK3B, and axin1 were purchased from 
Open Biosystems (Huntsville, AL). The deletion exon 8/9-GSK3B 
mutant was kindly provided by Catriona Jamieson (University of 
California, San Diego). We used a pUSE-AMP-myristoylated-Akt1 
vector for our Akt1 studies. cDNAs were cloned into the following 
mammalian expression vectors pCDNA6-CMV-V5/His (Invitrogen, 
Carlsbad, CA), pCMV-sport, or a modified pCDH1-EF1 vector 
evaluated FANCL steady-state levels or protein turnover (Figure 4, 
A and B). Conversely, suppression of GSK3B destabilized FANCL. 
We sought evidence to support the notion that this regulation is via 
phosphorylation through studies with the T178A-FANCL mutant, 
which has a disrupted putative GSK3B S/T-X-X-X-pS/pT motif. The 
steady-state expression of this mutant was reduced compared with 
wild-type FANCL, but its decay was similarly affected by GSK3B sup-
pression (Figure 4C). The caveat is that our studies do not discern 
whether the mutation at this site leads to direct loss of phosphoryla-
tion itself, affects the phosphorylation at a different site, or indirectly 
affects ubiquitination due to conformational changes of FANCL. 
Multiple serine and threonine sites are likely phosphorylated in 
FANCL (based on Figure 2G and phosphorylation prediction pro-
grams), and there may be key functional roles of each phosphory-
lated residue and phosphorylated combinations. We identified six 
potential serine and threonine phosphorylation sites in FANCL. 
Collectively our results show that GSK3B plays a role in stabilizing a 
pool of FANCL potentially in a multiprotein complex involving axin1. 
The fact that axin1 expression alone stabilizes FANCL suggests a 
stoichiometric requirement in this complex. Although the precise 
components of this complex have yet to be defined, it will be inter-
esting to determine whether the axin1 scaffold is able to recruit 
other kinases, in addition to GSK3B, to phosphorylate FANCL and 
protect it from degradation.
The PI3K/Akt signaling pathway regulates GSK3B and interfaces 
with multiple kinases (Chappell et al., 2011). We sought to deter-
mine the effects of these pathways on FANCL protein levels and 
ubiquitination. We found that in the cellular context of survival sig-
nals, FANCL protein levels are significantly stabilized (Figure 5, A–C). 
Accumulation of FANCL was associated with markedly reduced 
FANCL ubiquitination. These results are consistent with our finding 
that phosphorylation of FANCL is protective against proteasome-
FIGURE 6: Mechanisms of FANCL regulation by phosphorylation and ubiquitination. Our 
studies showed that FANCL is highly regulated by ubiquitin-mediated proteolysis. We depict in 
this model that steady-state FANCL levels are maintained, at least in part, by a complex 
involving GSK3B and axin1. A subset of phosphorylated forms of FANCL is not subject to 
ubiquitination based on 2D PAGE analysis, suggesting that upstream kinases might play a role in 
stabilizing a pool of FANCL and enhancing the functions of FANCL. Our work showed that the 
PI3k/Akt1 pathway modulates FANCL protein levels and is involved in suppressing 
polyubiquitination of FANCL, directly or indirectly. These studies position FANCL as a 
downstream effector of the PI3K/Akt1 pathway and link the Fanconi anemia pathway to a key 
pathway known to regulate survival and self-renewal of hematopoietic stem cells.
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of protein G plus agarose was added, and samples were incubated 
for an additional hour at 4°C with rocking. The beads were then 
washed four times with lysis buffer (as defined above). Proteins 
were resolved with SDS–PAGE, and ubiquitinated FANCL was de-
tected with an anti-HA antibody.
Measurement of protein stability
Whole-cell lysates were harvested at the indicated time points after 
the addition of cycloheximide at 50 µg/ml. Densitometric analysis of 
bands from immunoblots were quantified using ImageJ and ex-
pressed relative to time 0 for each condition. The half-life was deter-
mined based on the time at which the densitometry signal reached 
50% of the starting level.
Microscopy
For microscopy analysis, HeLa cells were fixed with 4% paraform-
aldehyde (pH 7.4 for 15 min at 37°C). Fixed cells were then per-
meabilized with 0.25% Triton X-100 in phosphate-buffered saline 
for 10 min at room temperature and stained with 4`,6-diamidino-2-
phenylindole (DAPI) to visualize nuclei. Cells were viewed and ana-
lyzed on a Zeiss Axio Observer.Z1 microscope using a 20r objec-
tive (Carl Zeiss, Jena, Germany). The JACoP plug-in for ImageJ 
was used to calculate Pearson’s coefficient for the analysis of colo-
calization of eGFP and the mCherry signals. For the z-stack imag-
ing, 14 images were obtained with a 63r oil objective at 0.423-µm 
increments obtained above and below focused nuclei. Quantita-
tive image cytometry was performed using an Olympus scan^R 
integrated imager and image analysis suite (Olympus-SIS, Mün-
ster, Germany) equipped with a Hamamatsu ORCA-R2 CCD digital 
camera (Hamamatsu Photonics, Tokyo, Japan; Rantala et al., 2013). 
Cells grown on coverslips were imaged with a 20r LUCPLFLN nu-
merical aperture 0.40 objective using specific filter sets for DAPI, 
GFP, and red fluorescent protein (Semrock, Rochester, NY). The 
scan^R image analysis software suite was used for quantitation of 
nuclear and cytoplasmic localization and signal intensity. The In-
cuCyte machine was use for real-time evaluation of fluorescence in 
live cells (Essen BioScience, Ann Arbor, MI). Transiently transfected 
HeLa cells were imaged for 48–72 h.
Flow cytometry
A minimum of 5000 events was generally obtained for each condi-
tion using the Guava EasyCyte Plus (Millipore, Billerica, MA). Gating 
was generated on a negative population or relative to a control or 
untreated condition. Within each experiment, the same analysis was 
applied to all samples. For the experiments shown in Figure 5D we 
expressed the shRNA as indicated for 48 h and then selected for 
puromycin resistance at 1 µg/ml for 3 d before analyzing eGFP 
expression.
Statistical analysis
Averages are from independent experiments with SD or SEM calcu-
lated to display variability. Student’s t test was performed using a 
two-tailed test.
(System Biosciences, Mountain View, CA). C-terminal eGFP and 
mCherry fusion proteins were cloned into the modified pCDH1-EF1 
vector. pRK5-HA-Ub wild-type and mutant constructs were obtained 
from Addgene (Cambridge, MA) deposited by Ted Dawson (Johns 
Hopkins University) and Sandra Weller (University of Connecticut 
Health Center; Lim et al., 2005; Livingston et al., 2009). GST pro-
teins were generated by cloning cDNAs into pGEX-4T constructs 
(GE Healthcare Life Sciences, Piscataway, NJ). Proteins were purified 
using glutathione cross-linked to Sepharose beads. The pLKO.1 
FANCL and Akt1 shRNA sets generated by the RNAi Consortium 
were purchased from Open Biosystems. Missense mutations were 
generated by site-directed mutagenesis per the manufacturer’s pro-
tocol (Agilent, Santa Clara, CA) and were confirmed by sequencing. 
The N-terminal deletion mutants of FANCL were generated with 
In-Fusion cloning (Clontech, Mountain View, CA).
Antibodies, Western blot analysis, and immunoprecipitation 
studies
FANCL, axin, GSK3B antibodies, and protein G plus agarose were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA). V5 antibody 
was obtained from AbD Serotec (Kidlington, United Kingdom). Other 
antibodies include anti–A-tubulin (Sigma-Aldrich, St. Louis, MO) and 
anti-hemagglutinin (mouse, Covance, Princeton, NJ; rabbit, Santa 
Cruz Biotechnology). Whole-cell lysates were lysed in buffer contain-
ing 0.5% Triton X-100, 120 mM NaCl, 50 mM Tris (pH 8.0), 2 mM 
EDTA, 1 mM Na2VO4, and 1:300 protease Inhibitor cocktail (P8340; 
Sigma-Aldrich). Proteins were resolved by SDS–PAGE. Densitometric 
analysis was performed using ImageJ software (National Institutes of 
Health, Bethesda, MD).
Nuclear extracts
Nuclear and cytoplasmic fractions from 293FT or HeLa cells were 
prepared essentially as described (Dao et al., 2012).
Phospho enrichment
A Pierce Phosphoprotein Enrichment Kit was used per the manufac-
turer’s instructions (Thermo Scientific Pierce, Rockford, IL). From 20 
to 40 µg of total protein from the various fractions was analyzed in 
immunoblots. Enrichment was determined by probing for phos-
phor-serine (Q5 antibody; Qiagen, Valencia, CA) and phosphor-
threonine (Q7 antibody; Qiagen). FANCL was probed to determine 
the fraction of FANCL subject to phosphorylation. We also immuno-
precipitated total FANCL and probed for phosphor-serine and 
phosphor-threonine. 293FT controls, without FANCL overexpres-
sion, were used to ensure that the protein being evaluated is in-
deed FANCL.
2D PAGE analysis
The ZOOM system was used for 2D PAGE analysis of cell extracts 
prepared by 2D solubilization buffer 1 (proprietary buffer purchased 
from the manufacturer) per the manufacturer’s protocol (Invitrogen). 
Calf intestinal alkaline phosphatase was added to cell extracts at a 
concentration of 1 unit/1 µg of total protein in 10 µl at 37ºC for 1 h. 
Desalting and buffer exchange were carried out with Zeba 7K 
MWCO columns (Pierce).
Cell-based ubiquitination assays
293FT cells were transfected with wild-type FANCL, C307A-FANCL, 
N-term–deletion FANCL mutant, or a GFP control, along with either 
wild-type or mutant HA-ubiquitin, using Lipofectamine 2000. 
Whole-cell extracts were incubated with 1–2 µg of anti-FANCL anti-
body and incubated at 4°C with rocking overnight. From 20 to 40 µl 
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